LEO Pharma, a global leader in medical dermatology delivering innovative solutions for skin health, announces that it has entered into a definitive agreement to acquire Replay, a gene therapy company focused on developing transformative treatments for rare genetic dermatological conditions. The acquisition adds deep expertise and a next-generation gene therapy platform to LEO Pharma’s pipeline through Replay’s high‑payload herpes simplex virus (HSV) delivery vector. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital.
Read the full article: LEO Pharma Bolsters Rare Skin Disease Focus through Acquisition of Replay Gene Therapy Platform //
Source: https://www.businesswire.com/news/home/20260430695749/en/LEO-Pharma-Bolsters-Rare-Skin-Disease-Focus-Through-Acquisition-of-Replay-Gene-Therapy-Platform